BioSpace News Archive

Organophosphates, like methyl-paraoxon, have grown in prominence as effective pest repellants for crops like cotton and legumes.

Evaxion Biotech A/S (NASDAQ: EVAX), announced today it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase 2b trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

VBL Therapeutics today announced the appointment of Matthew Trudeau to the newly created position of Chief Commercial Officer (CCO).

Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that its R&D team has used the company’s proprietary short oligo ligation assembly (SOLA) enzymatic DNA synthesis (EDS) technology to successfully construct the hemagglutinin (H1) and neuraminidase (N1) genes from the influenza A virus genome.

Dyne Therapeutics, Inc. (Nasdaq: DYN), today announced that the U.S. Food and Drug Administration (FDA) has placed on clinical hold its Investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.

SciSparc Ltd. (NASDAQ: SPRC), today announced that it has entered into an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel-Aviv Sourasky Medical School, in Tel-Aviv, Israel, to further its Phase IIb clinical study for SCI-110.

PTC Therapeutics, Inc. announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy.

Aktis Oncology today announced the expansion of their leadership team and scientific capabilities through the appointments of Tyler Benedum , PhD, as Senior Vice President, Head of Chemistry, Manufacturing, and Controls (CMC), and Daša Lipovšek, PhD, as Vice President, Head of Lead Discovery.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported that it has received an updated independent safety review of certain preliminary data for the first 30 patients in its three Phase 1 clinical trials with Annamycin targeting relapsed or refractory acute myeloid leukemia (AML) and the metastases of soft tissue sarcoma to the lungs (STS Lung).

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, today announced a license option agreement with Innovent Biologics, Inc. (HKEX: 01801) (“Innovent”) for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform.